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Summary
 
The heterodimeric CD94/NKG2A receptor, expressed by mouse natural killer (NK) cells,
transduces inhibitory signals upon recognition of its ligand, Qa-1
 
b
 
, a nonclassical major histo-
compatibility complex class Ib molecule. Here we clone and express two additional receptors,
CD94/NKG2C and CD94/NKG2E, which we show also bind to Qa-1
 
b
 
. Within their extra-
cellular carbohydrate recognition domains, NKG2C and NKG2E share extensive homology
with NKG2A (93–95% amino acid similarity); however, NKG2C/E receptors differ from
NKG2A in their cytoplasmic domains (only 33% similarity) and contain features that suggest
that CD94/NKG2C and CD94/NKG2E may be activating receptors. We employ a novel block-
ing anti-NKG2 monoclonal antibody to provide the first direct evidence that CD94/NKG2 mol-
ecules are the only Qa-1
 
b
 
 receptors on NK cells. Molecular analysis reveals that NKG2C and
 
NKG2E messages are extensively alternatively spliced and 
 
z
 
20-fold less abundant than
NKG2A message in NK cells. The organization of the mouse 
 
Cd94/Nkg2
 
 gene cluster, pre-
sented here, shows striking similarity with that of the human, arguing that the entire CD94/
NKG2 receptor system is relatively primitive in origin. Analysis of synonymous substitution
frequencies suggests that within a species, NKG2 genes may maintain similarities with each
other by concerted evolution, possibly involving gene conversion–like events. These findings
have implications for understanding NK cells and also raise new possibilities for the role of Qa-1
in immune responses.
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N
 
atural killer cells mediate innate immunity by secretion
of inflammatory cytokines and by direct cytotoxicity
against infected or transformed target cells (1, 2). NK cells
are regulated in part by several families of cell surface inhib-
itory receptors specific for various alleles of MHC class I (3, 4).
These receptors are organized into multiple families, in-
cluding (a) the killer cell Ig-like receptors (KIRs)
 
1
 
, expressed
in humans but not rodents; (b) the lectin-like Ly49 homo-
dimers expressed functionally in rodents but not, apparently,
in humans; and (c) the lectin-like heterodimers formed from
CD94 and NKG2 subunits, which are the only class I–specific
receptors found in both humans and rodents (for review see
reference 5). By virtue of their expression of these class I–spe-
cific inhibitory receptors, NK cells preferentially lyse targets
lacking appropriate class I MHC molecules. Thus, NK
cells may defend against viruses and tumors that downregu-
late host cell MHC class I so as to evade detection by T
cells (6–8).
An unusual feature of the CD94/NKG2 heterodimers is
that they recognize a nonclassical MHC class I ligand, HLA-E
in humans or Qa-1 in mice (9–12). Recognition of Qa-1
and HLA-E appears to require both the CD94 and NKG2
receptor subunits (9, 10). Surprisingly, HLA-E and Qa-1
are not recognizably orthologs at the level of overall amino
acid sequence (13). However, they are both able to bind
specifically and predominantly to a nine–amino acid pep-
tide derived from the signal sequences of some classical class
I molecules (14–18). In the mouse, this peptide is referred
to as Qdm (for ‘Qa-1 determinant modifier’) and has the se-
quence AMAPRTLLL (16). Although presumably cleaved
from the nascent class I polypeptide by an endoplasmic
reticulum–resident enzyme (‘signal peptidase’), Qdm will
not be presented by Qa-1 unless transported by TAP, the
transporter associated with antigen presentation (16, 19).
Functional evidence has demonstrated that NK cells will
not recognize cell surface Qa-1 unless Qdm (or possibly re-
lated peptides) is present (9, 20). Evidence also suggests that
 
1
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human CD94/NKG2 recognition of HLA-E may be ex-
quisitely sensitive to the sequence of the particular HLA-
E–bound peptide (21, 22). Taken together, these observa-
tions support an elegant mechanism by which NK cells can
specifically monitor TAP function and the biosynthesis of
highly polymorphic class I molecules by recognition of a
relatively nonpolymorphic molecule.
Several NKG2 isoforms have been described. In humans,
both the inhibitory CD94/NKG2A and the activating CD94/
NKG2C receptors have been shown to recognize HLA-E
(15, 22), but to date in mice, only the inhibitory CD94/
NKG2A receptor has been shown to interact with Qa-1
 
b
 
(9). The capacity of human CD94/NKG2C to activate NK
cells is due to its association with an immunoreceptor tyro-
sine-based activation motif–containing homodimer called
DAP12 (originally called KARAP; 23–25). It is not known
if mouse NKG2C, recently identified only at the message
level (26, 27), associates with mouse DAP12. Both mouse
and human NK cells also appear to express the NKG2D
molecule. However, NKG2D exhibits little sequence simi-
larity to other NKG2 molecules (see Fig. 1 B), does not ap-
pear to heterodimerize with CD94, and associates with the
DAP10 signaling module instead of DAP12 (28). More-
over, the ligand for NKG2D in humans was recently shown
to be a stress-induced class I–like molecule (29), arguing
that NKG2D is functionally distinct from other NKG2 re-
ceptors.
Among mammals, the only known peptide ligands for
CD94/NKG2 receptors are the Qdm-like peptides found
in class I signal sequences. However, several viruses encode
proteins containing Qa-1 or HLA-E binding peptides. For
example, the UL40 gene product of human CMV contains
the HLA-E binding peptide VMAPRTLIL within its sig-
nal sequence (available from SWISSPROT under accession
number P16780). Similarly, the mouse hepatitis virus he-
magglutinin (HA) esterase gene product contains the canon-
ical Qa-1 binding peptide AMAPRTLLL (13). It is tempt-
ing to speculate that these viruses may utilize these peptides
as ‘decoys’ to evade NK-mediated lysis through engagement
of the inhibitory CD94/NKG2A receptor. The existence of
NK cells expressing activating CD94/NKG2 receptors spe-
cific for HLA-E or Qa-1 complexes might then be impor-
tant in allowing the immune system to detect and lyse cells
displaying such viral decoys.
T cells have also been proposed to recognize Qa-1 in
various contexts (30–34). Although it seems reasonable to
presume that recognition of Qa-1 by T cells is mediated by
the TCR, it should be noted that ‘NK’ receptors (includ-
ing CD94 and NKG2 receptors) can be expressed by T
cells (35, 36), and it remains possible that some of the ef-
fects of Qa-1 on T cells might be due to T cell expression
of CD94/NKG2 heterodimers.
Although previous studies demonstrated that NK cells
can bind to soluble Qa-1 tetramers (9, 37), as can heterolo-
gous transfectants expressing CD94/NKG2A (9), it has never
been formally demonstrated that Qa-1 tetramer binding by
NK cells is due to NK expression of CD94/NKG2, and
moreover, additional Qa-1 receptors might exist. Here we
report the identification and characterization of two puta-
tive activating receptors on mouse NK cells, CD94/NKG2C
and CD94/NKG2E, which, we demonstrate, bind Qa-1
 
b
 
.
We also provide evidence that CD94/NKG2 receptors are
the only Qa-1 receptors on NK cells. Our results have im-
plications for our understanding of NK cells and the Qa-1
molecule and will permit dissection of the role of class I–spe-
cific activating receptors in the genetically and experimen-
tally amenable mouse model.
 
Materials and Methods
 
Primers, Probes, PCR, and Sequencing.
 
Table I contains a list of
PCR primers used in this study. For PCR, an annealing temper-
ature of 55
 
8
 
C was used throughout. Oligonucleotide probes
were hybridized to Southern blots at 50°C and washed twice
briefly in 2
 
3
 
 SSC/1% SDS at room temperature and then for
 
z
 
30 min at 50°C in 1
 
3
 
 SSC/1% SDS before exposure to film.
Sequencing reactions were performed using the Big Dye Termi-
nator Ready Mix (PE Biosystems) and were resolved and ana-
lyzed using an ABI Prism 310 sequencer (PE Biosystems).
 
Antibodies.
 
To generate anti-CD94/NKG2 mAbs, male Lewis
rats were immunized three times, at 
 
z
 
2-wk intervals, with stable
Chinese hamster ovary (CHO) cell transfectants expressing the
B6 alleles of CD94 and NKG2A. The rats were then boosted
with the same transfectants, and 3 d later spleen cells were fused
to P3X63-Ag8.653 (subclone of ATCC TIB-9) using PEG1500
(Boehringer Mannheim) according to the manufacturer’s instruc-
tions. HAT-resistant hybridoma supernatants were screened for
staining of NK1.1
 
1
 
 spleen cells and for staining of CHO–CD94/
NKG2A but not untransfected CHO cells. Hybridoma 20d5, spe-
cific for NKG2, and hybridoma 18d3, specific for CD94, were
cloned by serial dilution three times. Both mAbs are rat IgG2a
 
k
 
,
as assessed with a rat mAb isotyping kit (PharMingen) and were
purified from hybridoma supernatants over protein G agarose
(Boehringer Mannheim). Purified 20d5 was used to block NKG2
receptors at a concentration of 100 
 
m
 
g/ml. Anti-NK1.1 mAb was
purified from PK136 supernatants and conjugated to FITC. PE-
conjugated PK136 was purchased from PharMingen, and strepta-
vidin–PE was from Molecular Probes, Inc.
 
Molecular Cloning of NKG2C and NKG2E.
 
In the course of
amplifying NKG2 cDNA ends (as described previously; refer-
ence 9), one clone similar to human NKG2C was obtained but
was lacking its 5
 
9
 
 end and start codon. Based on this clone, a se-
quencing primer (NKG2C3
 
9
 
ex2) was designed and used to ob-
tain the sequence of the 5
 
9
 
 coding and untranslated regions (UTRs)
directly from bacterial artificial chromosome (BAC) B6-3 (clone
91i19). 3
 
9
 
 coding and untranslated sequence was obtained by se-
quencing the end of a genomic fragment, H3.5. Together, these
5
 
9
 
 and 3
 
9
 
 sequences were used to design two sets of primers to
amplify full length NKG2C and -E open reading frames (ORFs).
The NKG2C 5
 
9
 
 and 3
 
9
 
 UTR primers recognized sites just out-
side of the predicted ORF, whereas the NKG2C5
 
9
 
ATG and
NKG2C3
 
9
 
#3 primers bound just within the ORF. Both sets of
primers were used to amplify NKG2 sequences from oligo dT–
primed cDNA generated by standard methods from IL-2–cul-
tured NK cell RNA. The products, generated with Taq poly-
merase (Promega Corp.), were cloned directly into the T-tailed
T easy vector (Promega Corp.) and sequenced on both strands.
Clones generated with the UTR primer pair were designated
‘C-UTR’ or ‘E-UTR,’ whereas clones generated with the ATG
primer pair were designated ‘C-ORF’ or ‘E-ORF.’ Two clones, 
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E-UTR4 and C-ORF4, were found to encode full length NKG2E
and NKG2C, respectively, and the sequences were judged free of
PCR-induced coding errors based on comparisons of multiple
independent clones. Clone C-ORF4 is identical to sequences
previously reported to GenBank (26, 27). Clone E-UTR4 con-
tains a silent T
 
®
 
C mutation at nucleotide 414.
 
BACs and Genomic Analysis.
 
BACs were identified from the
Genome Systems C57BL/6 BAC library as previously described
(9). Two HindIII fragments of 3.5 and 9 kb that hybridized to an
NKG2A exon 5/6 probe were cloned into HindIII-digested
pBluescript SKII(
 
1
 
) (Stratagene Inc.) to generate clones H3.5 and
H9. These clones were sequenced using T3 and T7 primers, as
well as the following primers, to determine the exon/intron
boundaries for exons 4–7: NKG25
 
9
 
ex5, NKG23
 
9
 
ex5, NKG25
 
9
 
ex6,
NKG23
 
9
 
ex6, NKG25
 
9
 
ex7, and NKG23
 
9
 
#3.
 
Quantitation of NKG2A, NKG2C, and NKG2E mRNA.
 
Sorted purified (
 
.
 
98% pure) NK1.1
 
1
 
CD3
 
2
 
 IL-2–cultured NK
cells or nylon wool–passed, IL-2–cultured NK cells were used as
starting material to make total RNA using the Ultraspec II re-
agent (Biotecx Labs.). Approximately 2 
 
m
 
g of RNA was reverse
transcribed using an oligo-dT primer (GIBCO BRL), murine leu-
kemia virus reverse transcriptase (GIBCO BRL), dNTPs (Promega
Corp.), and RNasin RNase inhibitor (Promega Corp.) in a 20 
 
m
 
l
volume. 1 
 
m
 
l of the resulting cDNA was used as a template for 27
cycles of PCR using the NKG2C 5
 
9 
 
437 and NKG2C3
 
9
 
#3
primers, which bind to identical sites in all three NKG2 genes
and generate a product of 298 bp. 0.1 
 
m
 
l of 
 
a
 
-[
 
32
 
P]dCTP was
added to each 100-
 
m
 
l PCR reaction. 1–5 
 
m
 
l of each PCR reac-
tion was digested with gene-specific restriction enzymes: MboI
digests only NKG2A, at nucleotide 541; StuI digests only NKG2C,
at nucleotide 562; and PvuII digests only NKG2E, at nucleotide
617. The digests were resolved on 6.5% PAGE, and band intensi-
ties were quantified using PhosphorImager analysis (Molecular Dy-
namics). As controls, plasmids containing each of the cDNAs were
used as templates for the identical PCR and digestion protocol.
 
Stable CHO Transfectants and Qa-1 Tetramer Staining.
 
The ex-
pression vector for NKG2A has been described (9). To generate
expression constructs, NKG2C and -E were amplified from clones
C-ORF4 and E-UTR4 by PCR using Pfu polymerase (Strata-
gene Inc.), primer NKG2C5
 
9
 
ATG, and one of either primer
NKG2C3
 
9
 
#3 (used for NKG2C) or NKG2AHANot3
 
9
 
 (used for
NKG2E). The products were digested with XhoI and NotI, and
cloned into the pME18S expression vector (sequence available
from EMBL/GenBank/DDBJ under accession number AB009864),
and confirmed by sequencing. The latter primer added a nine–
amino acid HA epitope tag (amino acid sequence YPYDVPDYA)
to the COOH terminus (extracellular) of the NKG2E molecule,
allowing its detection with an anti-HA mAb. Previous results
with NKG2A–HA (9) showed the tag is unlikely to affect ligand
binding. For our studies, the tag proved unnecessary, as we were
subsequently successful in developing anti-NKG2 mAbs. The ex-
pression construct for NKG2C did not encode an HA-tagged
molecule. The pME18S expression vectors were stably trans-
fected into CHO cells along with a pIRES vector (Clontech) en-
coding mouse CD94 and the 
 
neo
 
 cDNA. NKG2E (but not
NKG2C) was also cotransfected with pME18S-DAP12, but re-
sulting clones were not assessed for DAP12 expression. Transfec-
tion was with the Lipofectamine reagent (GIBCO BRL) as previ-
ously described (38). 48 h after transfection, CHO cells were
passaged into RPMI supplemented with 1 mg/ml G418 (GIBCO
BRL). Once drug-resistant cells started to grow out, bulk trans-
fectants were sorted for bright surface expression of NKG2A, -C,
or -E using the 20d5 anti-NKG2 mAb or Qa-1 tetramer as stain-
ing reagent. After sorting, cells were cloned by limiting dilution,
and positive clones were expanded without G418. Qa-1 tetra-
mers, complexed with the Qdm peptide (AMAPRTLLL),
 
Table I.
 
Primers Used in This Study
 
Primer name Sequence (5
 
9
 
 to 3
 
9
 
)
NKG2C3
 
9
 
ex2 AAGGCTAAACTCCAGCAGGCGATCTCC
NKG2C3
 
9
 
#3 tatagcggccgcTCAGATGGGGAATTTACACTTACAAAGATATGG
NKG2C5
 
9
 
ATG atactcgagccaccATGAGTCACCTGCTTGGAACTG
NKG2C5
 
9
 
UTR CTCACTGGTCTACAGACAAG
NKG2C3
 
9
 
UTR CCTGGCAGACTTCCAGTGC(A/G)GGTGTTTCA
NKG2E-specific TATTACATTGGCATGGAAAGA
NKG2C/A-specific TATTTCATTGGTATGGAGAGA
NKG25
 
9
 
437 GAAAATCTTGGAATGACAGTTTGG
NKG25
 
9
 
ex5 GCACAGCCTTGTCCTCATTGTCC
NKG23
 
9
 
ex5 CTGCTCCTCTTCACTATCTATG
NKG25
 
9
 
ex6 CAATCTCTTTCACTGATCTCATGG
NKG23
 
9
 
ex6 GGTTTGAAAATTGAGACTTCTTTCC
NKG25
 
9
 
ex7 ATAGCAGAGATTCTCCATGATG
NKG2AHANot3
 
9
 
tatagcggccgcTCAGGCGTAGTCGGGCACGTCGTAGGGGTAGATGGGG-
AATTTACACTTACAAAG
NKG2C5
 
9
 
ex2 CCCAGAAGCATCTGAAGGCCAGCAGGCATGG
NKG2C3
 
9
 
575 CCTCTGCCCTTCCGAAGGATTCCAG
Restriction enzyme sites used for cloning are shown in lowercase. 
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were generated and used as described previously (9, 39), except
that a Superdex200 gel filtration column (Pharmacia) was used
in all purification steps.
 
Sequence Alignment and Analysis.
 
Nucleotide sequences were
aligned with CLUSTAL W (40), using the portion of each se-
quence corresponding to the carbohydrate recognition domain
(CRD) of NKG2A (taken here as the last 363 nucleotides of the
mNKG2A ORF). For each pair of aligned sequences, the program
DnaSP 3.0 (41) was used to calculate the number of synonymous
substitutions per synonymous site (Ks) and the number of nonsyn-
onymous substitutions per nonsynonymous site (Ka). This program
uses the unweighted algorithm of Nei and Gojobori (42), which
can be explained in brief. First, the total number of nonsynony-
mous sites (
 
N
 
, at which nucleotide changes give rise to amino acid
changes) and synonymous sites (
 
S
 
, at which nucleotide changes are
silent) are determined for each sequence, and the average values of
 
S
 
 and 
 
N
 
 for each pair of sequences are used. Then, for each pair of
sequences, the number of synonymous (
 
S
 
d
 
) and nonsynonymous
(
 
N
 
d
 
) nucleotide differences observed is determined. For a pair of
codons that differ by more than one nucleotide, the different possi-
ble evolutionary paths that could give rise to the observed change
need to be taken into account (different evolutionary paths can in-
volve different numbers of synonymous and nonsynonymous sub-
stitutions). In the unweighted algorithm, all of the different possi-
ble pathways are considered equally likely. 
 
S
 
/
 
S
 
d
 
 is the proportion
of synonymous differences, which is then used to estimate Ks. See
Nei and Gojobori (42) for more details.
 
Results and Discussion
 
Molecular Cloning of NKG2C and NKG2E.
 
In the course
of amplifying mouse NKG2A cDNA ends (see Materials
and Methods), we obtained the 3
 
9
 
 end of a cDNA that ex-
hibited similarity to human NKG2C. Based on genomic
sequence obtained from a BAC clone (clone 91i19), we were
able to design PCR primers to amplify the entire coding
region of an NKG2C cDNA from C57BL/6 mice. The
consensus sequence obtained was identical to the sequence
also reported recently by others (26, 27). In addition, we
also obtained a novel NKG2C-like cDNA that we termed
mouse NKG2E. It must be emphasized that mouse NKG2C
is no more related to human NKG2C than to human
NKG2E, nor does mouse NKG2E exhibit more similarity
to human NKG2E than to human NKG2C (Fig. 1 B). Thus,
the mouse NKG2C and NKG2E genes are named in the
order of their discovery, rather than on the basis of homol-
ogy to their human ‘counterparts.’
Mouse NKG2C and NKG2E are 91% identical to each
other at the amino acid level and are new members of the
rapidly expanding family of lectin-like receptors expressed
by NK cells. Mouse NKG2C and -E exhibit greatest ho-
mology with the extracellular CRD of mouse NKG2A
(
 
z
 
95% similar and 
 
z
 
93% identical at the amino acid level),
but this similarity disappears almost entirely outside of the
CRD (Fig. 1). The previously identified mouse NKG2D
molecule (38, 43), on the other hand, differs markedly
from the other NKG2 molecules and is in fact no more re-
lated to these molecules than it is to CD94 (Fig. 1 B).
These comparisons confirm that NKG2D is likely not a
bona fide NKG2 family member.
Unlike mouse NKG2A, mouse NKG2C and -E do not
contain immunoreceptor tyrosine-based inhibitory motif–
like sequences in their cytoplasmic tails. Instead, like human
NKG2C and -E, mouse NKG2C and -E appear to contain
Figure 1. (A) Alignment of mouse, human, and rat NKG2A, -C, and -E protein sequences. All of the sequences are compared with that of mouse
NKG2E. Period (.) indicates identity with mNKG2E; hyphen (-) indicates a gap to improve alignment; asterisk (*) indicates a residue that is identical to
all shown NKG2 sequences, whereas colon (:) indicates a residue that is similar. Mouse, rat, and human sequences are denoted by the prefixes m, r, and
h, respectively. Underline indicates the position of putative charged transmembrane residues. The boundaries of the transmembrane domain are contro-
versial and may or may not contain the positive charge. A ‘long’ transmembrane domain is shown here to highlight the similar positive charges within the
human, mouse, and rat molecules. Protein sequences were aligned using the CLUSTAL W v1.6 algorithm. (B) A tree dendrogram illustrates the relation-
ships between the various NKG2 and CD94 family members. Sequences were aligned with CLUSTAL W, and the dendrogram was generated with
Phylip 3.572. The sequence of mouse NKG2E is available from EMBL/GenBank/DDBJ under accession number AF195779. 
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a positively charged residue (arginine) in their transmembrane
domains. Notably, the position of the charged residue within
the transmembrane domain is slightly different between the
mouse and human molecules (Fig. 1 A). Similar charges have
been shown to play an important role in other receptors by
mediating associations with activating signaling subunits such
as DAP12 (44) or FcR
 
g
 
 (45), but there are no data on the
relevant signaling partner for mouse NKG2C or -E.
The cytoplasmic tails of mouse NKG2C and -E do not
appear to contain any obvious signaling motifs themselves,
although their length (64 amino acids) allows for the possi-
bility that at least some component of the signal transduc-
tion by NKG2C/E might be through their own receptor
tails. The tails do not share any regions of substantial ho-
mology with the human NKG2C/E molecules, with the
exception of an invariant four–amino acid motif (PPEK)
that is presumed to directly abut the cytoplasmic face of the
lipid bilayer. The role of this motif is not known.
 
NKG2 and CD94 mAbs Establish CD94/NKG2 as the
Predominant Qa-1 Receptor on NK Cells.
 
To study CD94/
NKG2 expression by NK cells, we have generated mAbs
against the mouse NKG2 and CD94 molecules. The speci-
 
ficity of these antibodies was confirmed by staining COS cells
that had been transiently transfected with CD94, NKG2, or
control (Ly49A) cDNAs (Fig. 2 A). The 18d3 mAb recog-
nized COS cells transfected with CD94 alone as well as
CD94/NKG2 cotransfectants, but it did not recognize
COS cells transfected with NKG2A alone. In contrast, the
20d5 mAb recognized COS cells transfected with NKG2A
alone as well as CD94/NKG2A cotransfectants. The 20d5
mAb also appears to recognize NKG2C and NKG2E, as
20d5 did not stain COS cells transfected with CD94 alone
but did stain CD94/NKG2C/DAP12 and CD94/NKG2E/
DAP12 transfectants (Fig. 2 A). NKG2C and NKG2E reach
the cell surface inefficiently when transfected alone into COS
cells (data not shown). Cotransfection with CD94 improved
surface expression, and the further addition of DAP12 had a
small additional effect (data not shown). As was previously
documented (9), CD94 and NKG2A did not require each
other to reach the cell surfaces of COS transfectants.
As shown previously (9, 37) and in Fig. 2 B, tetrameric
complexes of Qa-1/
 
b
 
2 
 
microglobulin/Qdm stain roughly
half of adult mouse NK cells. Although the Qa-1 tetramers
presumably bind CD94/NKG2 receptors on NK cells, this
has not been formally demonstrated, and the possibility re-
mains that NK cells express additional Qa-1 receptors. We
observed staining of NK1.1
 
1
 
 splenocytes with both the 18d3
(anti-CD94; data not shown) and 20d5 (anti-NKG2) mAbs
(Fig. 2 B), confirming that these molecules are indeed ex-
pressed on the surfaces of NK cells. As expected, the fre-
quency of tetramer-reactive NK1.1
 
1
 
 cells (48% in Fig. 2 B)
was similar to the frequency of NKG2
 
1
 
 cells (53% in Fig.
2 B). The frequency of tetramer-reactive NK cells was some-
what variable and sometimes lower than (but never higher
than) the frequency of 20d5
 
1
 
 cells, particularly as the tetramer
preparation aged. Similar variability has been previously ob-
served with class I tetramer recognition of Ly49 receptors and
its possible explanations discussed (46). To confirm that
CD94/NKG2 receptors are the predominant Qa-1 receptors
on NK cells, we attempted to block Qa-1 binding with the
20d5 (anti-NKG2) mAb (Fig. 2 B). We found that 20d5
completely blocked all binding of Qa-1 tetramers to NK1.1
 
1
 
splenocytes, strongly arguing that CD94/NKG2 receptors are
indeed the predominant, if not the only, Qa-1 receptors on
mouse NK cells. Similarly, it has been observed that anti–
human CD94 blocks all binding of HLA-E tetramers to the
human NKL cell line (10).
 
NKG2C and -E Recognize Qa-1
 
b
 
.
 
Based on the high de-
gree of similarity between the extracellular ligand binding do-
mains of NKG2A, -C, and -E, it is reasonable to hypothe-
size that CD94/NKGC and CD94/NKG2E heterodimers,
like CD94/NKG2A heterodimers, would recognize Qa-1
 
b
 
.
We generated stable transfectants of CHO cells expressing
high levels of CD94/NKG2A, CD94/NKG2C, and CD94/
NKG2E (Fig. 3). All three stable cell lines, but not untrans-
fected CHO cells, stained brightly with soluble, tetramer-
ized Qa-1/
 
b
 
2 
 
microglobulin/Qdm complexes. We previ-
ously showed that CD94 alone is incapable of binding
Qa-1
 
b
 
 (9). The results therefore provide direct evidence that
both CD94/NKG2C and CD94/NKG2E recognize Qa-1
 
b
 
–
Figure 2. (A) The 18d3 mAb recognizes mouse CD94, and the 20d5
mAb recognizes mouse NKG2A, -C, and -E. COS cells were transiently
transfected with expression vectors encoding the indicated cDNAs (as de-
scribed in Materials and Methods). The same batch of transfected cells was
stained with either 18d3 or 20d5 hybridoma supernatants, followed by
FITC-conjugated anti–rat IgG. Ly49A-transfected COS cells were used
as a negative control. (B) CD94/NKG2 receptors are the only detectable
Qa-1 receptors on NK cells. Nylon wool–nonadherent splenocytes were
preincubated with 2.4G2 (anti–FcgII/III receptor) supernatant, and in the
center panel with unconjugated 20d5 (anti-NKG2A/C/E) mAb. The
cells were then pelleted and stained with PK136 (anti-NK1.1; PE conju-
gate, left panel; FITC conjugate, center and right panels), streptavidin–
PE-complexed Qa-1 tetramers, and/or 20d5 FITC, as indicated. The
percentages of NK1.11 cells is indicated.1806 Recognition of Qa-1b by CD94/NKG2C and CD94/NKG2E
Qdm complexes. The degree of staining appeared to corre-
late roughly with the levels of NKG2 and CD94, as indepen-
dently assessed by staining with anti-NKG2 and anti-CD94
mAbs. In particular, the CD94/NKG2A transfectant stained
most brightly with tetramer and with anti-CD94 and anti-
NKG2 antibodies, whereas the CD94/NKG2C transfectant
stained least brightly with all three staining reagents. Thus,
our data do not reveal a gross difference in the avidity of
the various CD94/NKG2 subunits for Qa-1b. Evidence in
humans using quantitative surface plasmon resonance tech-
niques suggests that CD94/NKG2A binds HLA-E with
higher affinity than does CD94/NKG2C (21). Such differ-
ences may also exist for the mouse CD94/NKG2 receptors,
as our data is not quantitative. Because the Qa-1 protein was
produced in Escherichia coli and is therefore unglycosylated,
our results also demonstrate that CD94/NKG2C and CD94/
NKG2E, like CD94/NKG2A (9), can recognize carbohy-
drate-independent epitopes on their ligands.
Genomic Mapping and Structure of NKG2C and NKG2E.
Previous Southern blot data were consistent with a small clus-
ter of NKG2 genes located within the NK gene complex near
mouse CD94. To determine if the NKG2C and NKG2E
cDNAs we obtained might map to the CD94/NKG2 locus,
we designed an oligonucleotide probe specific for NKG2E, as
well as a probe that recognized NKG2C and NKG2A but not
NKG2E. These probes were tested for specificity on their cor-
responding cDNAs (not shown) and were then used on
Southern blots shown in Fig. 4. We found that a 3.5-kb
HindIII fragment, present in all the BACs, hybridized specifi-
cally to the NKG2E probe. In contrast, the NKG2A/C probe
hybridized specifically to a 9-kb HindIII fragment, present
only in BACs B6-1 and B6-4. The NKG2A/C probe also
recognized a z20-kb fragment present only in BAC B6-4,
the only BAC known to contain NKG2A (9). The 3.5- and
9-kb HindIII fragments were subcloned and partially se-
quenced and were found to contain sequence that perfectly
matched exons 4–7 of NKG2E and NKG2C, respectively
(exon numbering based on homology to the human NKG2A
gene; reference 47). The boundaries for the mouse exons are
presented in Table II. As described below, the boundaries of
exons 4 and 5 appear to be somewhat flexible and can give rise
to alternatively spliced transcripts.
Together with previously presented data (9, 48), these
results allow us to infer the order of mouse CD94 and
NKG2 genes within the NK complex on mouse chromo-
some 6 (Fig. 4 A). Interestingly, the overall structure of
the locus is well conserved with that of the human CD94/
NKG2 locus. In particular, the gene order CD94–NKG2D–
NKG2E/C–NKG2A appears to be conserved (49). The
human locus differs by the presence of NKG2F, a truncated
Figure 3. CD94/NKG2C and CD94/NKG2E are receptors for Qa-
1b. CHO cells were stably transfected with expression vectors encoding
CD94 and NKG2 cDNAs as described in Materials and Methods. Un-
transfected CHO cells or stable CHO transfectants were stained with PE-
complexed tetramers of soluble Qa-1b/Qdm class I molecules or with
streptavidin–PE as a negative control. The same cells were also stained
with FITC-conjugated 20d5 mAb (anti-NKG2) or with FITC-conju-
gated 18d3 mAb (anti-CD94). The mean fluorescence intensity (MFI) is
indicated for each histogram.
Figure 4. The mouse CD94/NKG2 gene clus-
ter. (A) Relative positions of Nkg2c and Nkg2e
within the C57BL/6 (B6) NK complex on mouse
chromosome six, as inferred in part from references
9 and 48 and the data presented in B. The map is
oriented with the centromere to the left. The Ge-
nome Systems clone number for each BAC clone is
indicated to the right of each clone; the numbers at
left are more convenient internal reference num-
bers. (B) Three BAC clones (B6-1, B6-3, and B6-
4) and two HindIII genomic subclones (H3.5 and
H9) were digested with HindIII, resolved by aga-
rose gel electrophoresis, and analyzed by Southern
blot. The blot was probed with an oligonucleotide
probe specific for Nkg2e, stripped, and then re-
probed with an oligonucleotide probe specific for
Nkg2c and Nkg2a (but not Nkg2e).1807 Vance et al.
Table II. Splice Acceptors and Donors in NKG2C and NKG2E
Gene Exon Splice Sequence
E 4 Acceptor agagtgactttaactctccagATGCTGAACTGAAGAAG...(exon)...
Donor ...CAGATCCACCCCTTCTTGgttagaacccagaaa...(intron)...
C 4 Acceptor agagtgactttaactctccagATGCTGAACTGAAGAAGCAGATCCACCCCTTCTTGGTTAGAA...(exon)...
Donor ...TTGCTCTCCAAAGgtctgatgtttatgcacattctattt...(intron)... 
E 5 Acceptor attttgattccagATATAAACCACAGTCTATCTTCAGCACAAACTTATGCTCTTTGTCCAA...(exon)...
Donor Not determined
C 5 Acceptor atgttgcctctagatataaactacactctatcttcagCACAGCCTTGTCCTCATTGTCCAAAGGAGTGGAT...(exon)...
Donor ...TTCACATAGATAGTGAAGAGGAGCAGgtaagagctgacatgtg...(intron)...
E 6 Acceptor gcttctctggtagGACTTTCTGCAATCCCTTTCACTGGTCTCATGGACTGGAATCCTTCGGA...(exon)...
Donor ...AAGACTCAACTTTCAAACCAAAgtaagttatcatgaaag...(intron)...
C 6 Acceptor ggttctctggtagGATTTTCTGCAATCTCTTTCACTGGTCTCATGGACTGGAATCCTTCGGA...(exon)...
Donor AAGACTCAATTTTCAAACCAAAgtaagtttttaag...(intron)...
E 7 Acceptor atttgcaccattgtagGATAGCAGAGATTCTCCAT...(exon)...
C 7 Acceptor atttgcaccattgtagGATAGCAGAGATTTCCCAT...(exon)...
Intronic sequence (based on clones C-ORF4 and E-UTR4) is shown in lowercase. The invariant dinucleotide donors (gt) or acceptors (ag) at the
edges of introns are underlined, as are alternative donors or acceptors used in alternatively spliced transcripts.
NKG2 gene that lies between NKG2D and NKG2E (49,
50). We have not seen evidence of a mouse NKG2F gene,
although its existence cannot be ruled out.
NKG2C and NKG2E Are Extensively Alternatively Spliced. In
addition to the cDNA clones encoding full length
NKG2C and NKG2E, we obtained multiple clones encod-
ing NKG2C- or NKG2E-like sequences that differed by
various insertions and deletions (Fig. 5). The positions of
the insertions and/or deletions corresponded precisely to
canonical splice acceptors and donors determined from the
Figure 5. Alternative splicing of
Nkg2c and Nkg2e genes. Exons found to
be involved in alternative splices are
shown as boxes at the top, and various
cDNA clones sequenced are depicted
below. The portions of the cDNA se-
quences depicted with a solid black line
are predicted to be translatable, whereas
the portions of the cDNA depicted with
a stippled line are predicted to follow an
in-frame stop codon. Only clones en-
coding NKG2E1, -C1, or -C2 are pre-
dicted to generate full length protein,
and the nucleotide positions of in-frame
stop codons are indicated in parentheses.
Exon–intron boundaries were con-
firmed by direct sequencing of genomic
clones, but the distances between exons
were not determined. Dashed vertical
lines within exons represent the pres-
ence of cryptic splice acceptors or donors. Based on sequence polymorphisms between NKG2C and -E, clone E-UTR1 appears to be a fusion of tran-
scripts from both genes. This might represent an artifact of PCR, or it may have been generated in vivo. The exons are numbered according to homol-
ogy with the human NKG2A gene. The C2 sequence was not obtained in this study but was found previously (26). Additional splice variants appear to
exist (Fig. 6) but have not yet been cloned and sequenced.1808 Recognition of Qa-1b by CD94/NKG2C and CD94/NKG2E
genomic sequencing (Table II), and so it seems unlikely
that these variants were an artifact of PCR. Rather, they
probably arose by alternative splicing of primary NKG2C
and NKG2E transcripts. The splice variants all involve al-
ternative splice donors or acceptors present in exons 4 and
5, encoding the extracellular stalk and part of the CRD.
Alternative splicing of other exons was not observed. Some
of the variants produce reading frame shifts that result in
premature stop codons and truncated receptors that would
not be predicted to bind ligand (Fig. 5). A previously iden-
tified NKG2C cDNA called NKG2C2 (26) likely arose from
alternative use of the splice acceptors and donors identified
here. One particularly interesting clone was E-UTR1, which
was found to contain a chimeric NKG2C/NKG2E cDNA
(Fig. 5). It is possible that this transcript was generated as an
artifact of PCR. Alternatively, if NKG2C and -E share the
same transcriptional orientation in the genome as they do
in humans, it is possible that a single primary message en-
coding both genes was transcribed and spliced to form the
chimeric receptor. Alternative splicing, particularly involv-
ing exons encoding the transmembrane and stalk domains,
has also been observed for other C-type lectin-like recep-
tors, including mouse Ly49 C, D, G, H, and J, human CD94,
and human and mouse NKG2B, a splice variant of NKG2A
(27, 47, 51–54). Despite their apparent prevalence, the func-
tion of these alternative splices is not clear.
To estimate the relative abundance of the splice variants
in NK cells, we amplified the alternatively spliced region
from various NK cell cDNA samples using flanking primers
that recognize NKG2C and NKG2E but not NKG2A.
The heterogeneous PCR product was resolved by gel elec-
trophoresis and then analyzed by Southern blot and probed
with NKG2C- and NKG2E-specific oligonucleotide probes
(Fig. 6). The results confirm that NKG2C and -E are in-
deed extensively alternatively spliced, and a total of eight
different cDNA variants could be detected. The pattern of
splicing detected was remarkably consistent in five different
RNA samples (Fig. 6), including RNA from highly puri-
fied (.98% pure) NK1.11CD32 NK cells. Control PCR
reactions using an equimolar mix of templates suggested
that shorter products were not preferentially amplified (data
not shown). Interestingly, although NKG2C and NKG2E
are closely related genes, they exhibit quite different pat-
terns of mRNA splicing. The majority of NKG2C cDNAs
are identical in size to the NKG2C1 cDNA and would
therefore be capable of producing a full length protein. On
Figure 6. NKG2C and NKG2E
are extensively alternatively spliced.
(A) PCR primers (59ex2 and
39575) flanking the region that is
alternatively spliced were used to
amplify product from control tem-
plates and from various cDNA
samples. The PCR products were
resolved on a 3% agarose gel and
stained with ethidium bromide.
The control templates were: –, dis-
tilled water; A, NKG2A cDNA;
1, NKG2E clone E-UTR1; 2,
NKG2E clone E-UTR2; E1,
NKG2E clone E-UTR4, which
encodes a full length protein,
NKG2E1; 3, NKG2E clone
E-ORF3; and C1, NKG2C
clone  C-ORF4, which encodes a
full length protein, NKG2C1.
cDNA samples were derived from RNA obtained from: 1, highly purified,
IL-2–cultured NK1.11CD32 NK cells; 2, highly purified, IL-2–cultured
NK1.11CD32 NK cells that had also been sorted for expression of NKG2
using the 20d5 mAb; 3, unsorted IL-2–cultured LAK (lymphokine-activated
killer) cells, preparation A; 4, unsorted IL-2–cultured LAK cells, preparation
B; and 5, unsorted IL-2–cultured LAK cells, preparation C. A total of eight
distinct bands were visible, although some were very weak. Based on South-
ern blot experiments (B and C), these bands could be assigned to either
NKG2E or NKG2C, as indicated on the right side of the gel. (B) The agarose
gel shown in A was analyzed by Southern blot and probed with an oligonu-
cleotide probe (E-probe), which recognizes NKG2E but not NKG2C. (C)
The blot was then stripped and reprobed with an oligonucleotide probe (C-
probe), which recognizes NKG2C but not NKG2E. The right portion of the
blot was exposed longer than the left to enhance detection of weaker bands
and prevent overexposure of the brighter control bands. It should be noted
that not all splice variants detected by this method have been cloned. The
NKG2C2 splice variant was only very weakly visible.
Figure 7. NKG2A message represents z95% of
the total NKG2 message in NK cells. Primers rec-
ognizing NKG2A, -C, and -E equivalently were
used to amplify NKG2 cDNA in a PCR reaction
containing a-[32P]–labeled nucleotides. The prim-
ers span a region of the NKG2 transcripts not af-
fected by alternative splicing. PCR products were
digested by the indicated enzymes and resolved on
6.5% PAGE. A control reaction with no template
did not result in any detectable product (not
shown). S1P is a double digest with StuI and
PvuII. RNA was made from nylon wool–passed
splenocytes cultured for 4 d in IL-2 (unsorted LAK
cDNA) or from sorted, purified (.98% pure)
IL-2–cultured NK cells (NK1.11CD32). Very
weak bands (not clearly visible in the figure) were
detected by longer exposure for the StuI and PvuII
digests of PCR products derived from cDNA. The
percentage of PCR product digested in each lane
by the indicated restriction enzyme is shown and
was quantified using PhosphorImager analysis.1809 Vance et al.
the other hand, the majority of NKG2E cDNAs are con-
siderably shorter and identical in size to the E-UTR2
cDNA. This cDNA contains a frame shift as compared with
the full length ORF. Consequently, most NKG2E cDNAs
are predicted to encode a truncated polypeptide that is un-
able to bind ligand. We conclude that a substantial fraction
of the NKG2C and -E message in NK cells is of an alterna-
tively spliced form.
NKG2A Transcripts Are Substantially More Abundant than
NKG2C and -E Transcripts. Previously, we observed that
Qa-1 tetramer–reactive NK cells (presumably expressing
CD94/NKG2A, -C, and/or -E) were inhibited, not acti-
vated, by the presence of Qa-1–Qdm complexes on target
cells. These data raised the possibility that the activating
NKG2C and NKG2E receptors might be expressed less
frequently than the inhibitory NKG2A receptor. Alterna-
tively, mouse NKG2C and -E might recognize Qa-1 rela-
tively poorly or transmit weaker signals. To distinguish
these nonexclusive possibilities, we developed a PCR-based
assay to quantitate the relative levels of NKG2A, -C, and -E
message in purified NK cells. We took advantage of the
high degree of nucleotide identity among the three cDNAs
to design a primer pair that would match perfectly to all
three cDNAs. As the primer binding sites and the size of
the amplified product is identical for all three sequences,
PCR should faithfully amplify each cDNA in proportion
to its representation in the original sample. The various
amplified cDNA products could be distinguished after PCR
by differential digestion with gene-specific restriction en-
zymes. Radioactive nucleotides were included in the am-
plification reaction to permit quantification of the various
digested PCR products by PhosphorImager analysis. The
results (Fig. 7) show that the majority of NKG2 PCR prod-
uct could be digested with an NKG2A-specific restriction
enzyme, MboI, whereas only a small fraction of the prod-
uct could be digested with NKG2C- and NKG2E-specific
restriction enzymes (PvuII and StuI). Using this method,
we estimated that NKG2A transcripts are at least 20-fold
more abundant than NKG2C and -E transcripts combined.
It is unclear whether this difference is best accounted for by
the presence of relatively few NKG2C/E1 NK cells or by
relatively low NKG2C/E transcript levels per cell. Never-
theless, our molecular analysis suggests that the net inhibi-
tion of NK cells by Qa-1 expressed on target cells may be
explained, at least in part, by the low abundance of activat-
ing NKG2C/E receptors on NK cells. It should be empha-
sized that activating NKG2 genes have been evolutionarily
conserved, and it thus seems likely that NKG2C/E genes
play an important role that does not depend on abundant
mRNA transcripts.
Evolution of Class I Receptors by NK Cells. The above find-
ings document the striking conservation of the function
and genomic organization of CD94/NKG2 receptors be-
tween mice and humans. In contrast, other class I–specific
receptors, such as Ly49 receptors in mice and KIRs in hu-
mans, do not appear to be functionally conserved. Given
the availability of NKG2 sequences from three species, it is
interesting to analyze the evolutionary history of these
genes. We therefore aligned the extracellular CRDs for each
possible pair of NKG2 genes from mice, rats, and humans.
Using the DnaSP algorithm (41), each aligned nucleotide
position was designated as a synonymous site (at which nu-
Table III. Calculation* of Number of Substitutions per 
Synonomous Site (Ks) and per Nonsynonomous Site (Ka) for the 
CRDs‡ of Various NKG2 Sequences
Comparison Synonomous sites
Nonsynonomous
sites
Sequence 1 Sequence 2 Number Ks Number Ka
Mouse vs. Mouse
mNKG2A mNKG2E 77.75 0.1257 285.25 0.0359
mNKG2A mNKG2C 76.33 0.0000 286.67 0.0321
mNKG2E mNKG2C 77.42 0.1263 285.58 0.0545
Mouse vs. Human
mNKG2A hNKG2A 77.67 0.6369 285.33 0.4256
mNKG2A hNKG2C 77.67 0.6026 285.33 0.4266
mNKG2A hNKG2E 77.50 0.6886 285.50 0.4595
mNKG2E hNKG2A 78.75 0.6330 284.25 0.4319
mNKG2E hNKG2C 78.75 0.5993 284.25 0.4330
mNKG2E hNKG2E 78.58 0.6836 284.42 0.4662
mNKG2C hNKG2A 77.33 0.6262 285.67 0.4532
mNKG2C hNKG2C 77.33 0.5922 285.67 0.4543
mNKG2C hNKG2E 77.17 0.6773 285.83 0.4750
Human vs. Human
hNKG2A hNKG2C 78.67 0.0259 284.33 0.0250
hNKG2A hNKG2E 78.50 0.0925 284.50 0.1184
hNKG2C hNKG2E 78.50 0.0998 284.50 0.1123
Rat Comparisons
mNKG2A rNKG2A 77.58 0.2064 285.42 0.1339
mNKG2A rNKG2C 77.25 0.1906 285.75 0.1593
mNKG2E rNKG2A 78.67 0.2730 284.33 0.1345
mNKG2E rNKG2C 78.33 0.2384 284.67 0.1599
mNKG2C rNKG2A 77.25 0.2103 285.75 0.1414
mNKG2C rNKG2C 76.92 0.1943 286.08 0.1627
rNKG2A rNKG2C 78.17 0.0669 284.83 0.0360
rNKG2A hNKG2A 78.58 0.7132 284.42 0.4603
rNKG2A hNKG2C 78.58 0.6706 284.42 0.4624
rNKG2A hNKG2E 78.42 0.7354 284.58 0.4959
rNKG2C hNKG2A 78.25 0.7073 284.75 0.4748
rNKG2C hNKG2C 78.25 0.6648 284.75 0.4704
rNKG2C hNKG2E 78.08 0.6491 284.92 0.5076
m, mouse; h, human; r, rat.
*All calculations performed with DnaSP version 3.0.
‡Defined here as the last 363 nucleotides of mNKG2A. Alignment was
performed using CLUSTAL W.1810 Recognition of Qa-1b by CD94/NKG2C and CD94/NKG2E
cleotide substitutions do not generate amino acid substitu-
tions) or as a nonsynonymous site (at which nucleotide sub-
stitutions generate amino acid substitutions; see Materials
and Methods). For each pair of aligned sequences we could
then estimate Ks, a commonly used parameter that repre-
sents the number of synonymous substitutions that have
occurred per synonymous site (Table III). The number of
nonsynonymous substitutions per nonsynonymous site, Ka,
could be similarly calculated. Synonymous (or ‘silent’) sub-
stitutions are usually considered selectively neutral, or nearly
so. Thus, a high Ks value reflects the substantial selection-
independent accumulation of nucleotide differences (55). The
analysis demonstrates that within a species, NKG2 sequences
are closely related, whereas between species they are not. The
intraspecies similarity is most dramatically exemplified by the
finding that there are, for example, no synonymous substitu-
tions within the CRDs of mouse NKG2A and mouse
NKG2C. Other intraspecies pairs of NKG2 genes give simi-
larly low frequencies of synonymous substitution, i.e., 0.03–
0.13 (Table III). In contrast, the frequency of synonymous
substitutions for interspecies pairs of NKG2 genes is substan-
tially higher, i.e., 0.60–0.68 (Table III).
These data are consistent with two broad evolutionary
histories: (a) humans and rodents share a single ancestral
NKG2 gene that underwent duplications separately in each
lineage to generate ‘independent’ and relatively young
multigene families; or (b) the common ancestor of humans
and rodents contained all three genes, but the genes have
since been undergoing ‘concerted evolution,’ a process by
which homologous loci within a species maintain similarity
to each other. Concerted evolution has been inferred in
several multigene families (55). The mechanisms by which
it occurs remain unclear but are thought to involve homoge-
nizing events, such as unequal crossing over and/or gene
conversion–like events (55).
Although it is difficult to adjudicate between the two
above evolutionary histories, the second model may be
more likely for the following reasons. First, all three species
examined contain multiple NKG2 genes, including at least
one inhibitory and one activating type, consistent with a
primitive duplication event that was transmitted to all lin-
eages. Second, the 59 (cytoplasmic) portions of the inhibi-
tory and activating NKG2 genes tend to vary substantially
from each other, even within species, suggesting that the genes
have been diverging for some time. Unless gene conversion–
like events—which can affect discrete parts of genes—are in-
voked, it is difficult to reconcile the evolutionary divergence
apparent in the 59 portions of mouse NKG2A and -C with
the finding that they do not exhibit any synonymous sub-
stitutions in their CRDs. Lastly, the remarkable overall
similarity seen in the genomic structures of the mouse and
human NKG2 loci (Fig. 4 and reference 49) suggests that
the gene families did not result from independent duplica-
tion events. It is interesting that gene conversion events
have also been proposed to play a role in the evolution of
MHC class I genes (56).
Our previous work on mouse CD94/NKG2A provided
evidence that recognition of class I was a primitive function
of NK cells that predated the divergence of mouse and hu-
man ancestors. Assuming that NKG2 genes underwent a
primitive duplication, as argued above, our work seems to
suggest that both activating and inhibitory class I recogni-
tion may have been primitive functions of NK cells. This is
interesting, as it suggests some fundamental role for activat-
ing receptors in the recognition of class I. This notion is fur-
ther supported by the observation that families of class I–spe-
cific receptors, including Ly49, KIR, and leukocyte Ig-like
receptors/Ig-like transcript families, invariably consist of
both activating and inhibitory paralogs. Indeed, the pairing
of inhibitory and activating isoforms extends beyond re-
ceptors specific for class I, and includes the paired Ig-like
receptors on B cells and myeloid cells (57) and the CD28/
CTLA-4 coreceptors on T cells. Although well under-
stood in the case of T cells, the molecular logic behind the
existence of paralogous activating and inhibitory receptors
on NK cells is still a matter of conjecture. We anticipate
that the identification of mouse CD94/NKG2C and
CD94/NKG2E as activating receptors will permit the ap-
propriate in vivo experimental manipulations required to
dissect their function.
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